Oncology · ImmunotherapyTrial Updateclinicalmid-term

Phase III Trial of Durvalumab with Chemotherapy in Stage II-III Breast Cancer

Importance8/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AstraZeneca66 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/17/2026, 12:32:07 AM

Assessment confidence: 51% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing phase III trial of durvalumab in combination with standard chemotherapy could significantly alter treatment protocols for breast cancer. Successful outcomes may enhance durvalumab's market position and influence competitive dynamics in the oncology landscape. Regulatory context from FDA (FDA AP — ONTRUZANT (SUPPL)) supports the near-term read. Assessment grounded in 13 ranked evidence items (2 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential of durvalumab in combination therapies and consider implications for market positioning in breast cancer. The strongest clinical anchor is Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer (ClinicalTrials.gov), sub-indication match (her2); mechanism alignment (her2). In her2, 8 regulatory and 0 competitive items passed relevance filtering for AstraZeneca.

Competitive Pressure

The most relevant competitive pressure comes from If successful, this trial could position durvalumab as a key combination therapy in breast cancer, impacting competitive dynamics among existing treatments..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ONTRUZANT (SUPPL) (FDA). Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda). The trial results will be critical for potential regulatory approvals and labeling changes, which could facilitate broader adoption of durvalumab in clinical practice.

Key Risks

Elevated medium regulatory exposure for AstraZeneca could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.

Key Opportunities

If durvalumab proves effective in this trial, it could capture substantial market share in breast cancer treatment, impacting revenue streams for both AstraZeneca and its competitors.
Upside for AstraZeneca may improve if Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the potential of durvalumab in combination therapies and consider implications for market positioning in breast cancer.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any announcements regarding efficacy and safety outcomes for the combination therapy.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ONTRUZANT (SUPPL)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PHESGO (SUPPL)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HERCEPTIN (SUPPL)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ONTRUZANT (SUPPL)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HERCEPTIN HYLECTA (SUPPL)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HERCEPTIN (SUPPL)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ENHERTU (SUPPL)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
FDA AP — ENHERTU (SUPPL)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (her2); Mechanism alignment (HER2)
FDA document
View source
Testing the Addition of New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
ClinicalTrials.govmedium relevance
Entity match (oncology)
FDA document
View source
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
ClinicalTrials.govlow relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
ClinicalTrials.govlow relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

No evidence in this category.

STARD10 promotes progression of HER2+ breast cancer and intracellular lipid metabolism via the cAMP/PKA/CREB1 signaling axis.
PubMedhigh relevance
Sub-indication match (her2); Mechanism alignment (HER2)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Entity match (oncology)
FDA document
View source
Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedmedium relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

AstraZeneca
Durvalumab
breast cancer
Oncology

Commercial impact

high

If durvalumab proves effective in this trial, it could capture substantial market share in breast cancer treatment, impacting revenue streams for both AstraZeneca and its competitors.

Regulatory impact

medium

The trial results will be critical for potential regulatory approvals and labeling changes, which could facilitate broader adoption of durvalumab in clinical practice.

What to watch

Monitor trial results and any announcements regarding efficacy and safety outcomes for the combination therapy.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.

Signals